

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 10-Q/A**  
**Amendment No. 1**

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, 2023**

or

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number **333-255266**

**UPEXI, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction of  
incorporation or organization)

**83-3378978**

(IRS Employer  
Identification No.)

**17129 US Hwy 19 N.  
Clearwater, FL**

(Address of principal executive offices)

**33760**

(Zip Code)

**(701) 353-5425**

(Registrant's telephone number, including area code)

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	UPXI	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated Filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)  YES  NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of May 12, 2023, the registrant had 18,094,748 shares of common stock, par value \$0.001 per share, outstanding.

#### EXPLANATORY NOTE

Upexi, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to amend the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Original Filing”), as originally filed with the Securities and Exchange Commission (the “Commission”) on May 15, 2023 (the “Original Filing Date”). This Amendment is being filed solely to update the revenue from acquisitions included in the financial statements and the net revenue included in the three months ended within disclosure Note 2. Acquisitions, which was inadvertently reported as the same revenue as included in the three months ended December 31, 2022, in the Original Filing.

In addition, in connection with the filing of this Amendment, the Company is including new certifications of the Company’s chief executive officer and chief financial officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company is not including new certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code because no financial statements are being filed with this Amendment.

This Amendment does not modify or update in any way the disclosures contained in, or exhibits filed or furnished with the Original Filing other than as set forth above. The Amendment does not modify or update in any way the total revenue, net income, assets, liabilities, equity or cash flows reported for the three and nine months ended March 31, 2023.

---

## TABLE OF CONTENTS

### PART I - FINANCIAL INFORMATION

<u>Item 1.</u>	<u>Interim Unaudited Condensed Consolidated Financial Statements</u>	<u>4</u>
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>39</u>
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>34</u>
<u>Item 4.</u>	<u>Controls and Procedures</u>	<u>34</u>

### PART II - OTHER INFORMATION

<u>Item 1.</u>	<u>Legal Proceedings</u>	<u>35</u>
<u>Item 1A.</u>	<u>Risk Factors</u>	<u>35</u>
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>35</u>
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	<u>35</u>
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	<u>35</u>
<u>Item 5.</u>	<u>Other Information</u>	<u>35</u>
<u>Item 6.</u>	<u>Exhibits</u>	<u>36</u>
<u>SIGNATURES</u>		<u>37</u>

## **FORWARD-LOOKING STATEMENTS**

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, such as the COVID-19 outbreak and associated business disruptions including delayed clinical trials and laboratory resources, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

Our unaudited condensed consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to shares of our common stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Upexi, Inc., unless otherwise indicated.

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**UPEXI, INC.**

**Interim Unaudited Condensed Consolidated Financial Statements  
For the Three and Nine Month Periods Ended March 31, 2023 and 2022**

	<b>Page</b>
<a href="#">Condensed Consolidated Balance Sheets as of March 31, 2023 and June 30, 2022 (Unaudited)</a>	5
<a href="#">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2023 and 2022 (Unaudited)</a>	6
<a href="#">Condensed Consolidated Statements of Stockholders' Equity for the Nine Months Ended March 31, 2023 and 2022 (Unaudited)</a>	7
<a href="#">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2023 and 2022 (Unaudited)</a>	8
<a href="#">Notes to the Unaudited Condensed Consolidated Financial Statements</a>	9

**UPEXI, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)**

	<b>March 31, 2023</b>	<b>June 30, 2022</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash	\$ 1,181,042	\$ 7,149,806
Accounts receivable	5,346,853	1,137,637
Inventory	10,140,644	4,725,685
Due from Bloomios	1,617,216	-
Deferred tax asset, current	-	462,070
Prepaid expenses and other receivables	1,809,730	840,193
Assets of discontinued operations, net	-	6,449,210
Total current assets	<u>20,095,485</u>	<u>20,764,601</u>
Property and equipment, net	7,618,148	7,343,783
Intangible assets, net	17,312,833	10,641,382
Goodwill	15,056,856	5,887,393
Deferred tax asset	2,979,918	2,002,759
Investments - Bloomios	9,955,450	-
Other assets	118,040	100,372
Right-of-use asset	678,145	926,570
Total other assets	<u>53,719,390</u>	<u>26,902,259</u>
Total assets	<u>\$ 73,814,875</u>	<u>\$ 47,666,860</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 2,635,876	\$ 2,018,541
Accrued compensation	889,634	531,259
Deferred revenue	48,162	105,848
Accrued liabilities	4,172,455	955,327
Acquisition payable	500,000	-
Current portion of notes payable	9,164,189	5,424,752
Current portion of operating lease payable	272,116	267,029
Total current liabilities	<u>17,682,429</u>	<u>9,302,756</u>
Operating lease payable, net of current portion	449,874	700,411
Notes payable, net of current portion	18,951,762	8,876,949
Total long-term liabilities	<u>19,401,636</u>	<u>9,577,360</u>
Commitments and contingencies		
<b>Stockholders' equity</b>		
Preferred stock, \$0.001 par value, 100,000,000 shares authorized, 500,000 and 500,000 shares issued and outstanding, respectively	500	500
Common stock, \$0.001 par value, 100,000,000 shares authorized, 18,094,748 and 16,713,345 shares issued and outstanding, respectively	18,094	16,713
Additional paid in capital	44,858,392	34,985,597
Accumulated deficit	(7,842,606)	(6,270,886)
Total stockholders' equity attributable to Upexi, Inc.	<u>37,034,380</u>	<u>28,731,924</u>
Non-controlling interest in subsidiary	(303,570)	54,820
Total stockholders' equity	<u>36,730,810</u>	<u>28,786,744</u>
Total liabilities and stockholders' equity	<u>\$ 73,814,875</u>	<u>\$ 47,666,860</u>

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

**UPEXI, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)**

	<b>Three Months Ended March 31,</b>		<b>Nine Months Ended March 31,</b>	
	<b>2023</b>	<b>2022</b>	<b>2023</b>	<b>2022</b>
<b>Revenue</b>				
Revenue	\$ 24,219,445	\$ 4,426,898	\$ 62,863,128	\$ 13,280,565
Cost of Revenue	14,614,754	1,098,137	36,904,527	3,081,112
Gross profit	<u>9,604,691</u>	<u>3,328,761</u>	<u>25,958,601</u>	<u>10,199,453</u>
<b>Operating expenses</b>				
Sales and marketing	3,476,918	1,085,823	9,210,303	3,821,081
Distribution costs	2,578,180	605,368	8,641,559	1,538,830
General and administrative expenses	2,878,255	1,970,276	8,287,779	6,556,627
Share-based compensation	1,146,299	854,013	3,126,472	2,333,306
Amortization of acquired intangible assets	1,691,243	236,001	3,534,216	540,836
Depreciation	232,492	115,011	669,540	361,590
	<u>12,003,387</u>	<u>4,866,492</u>	<u>33,469,869</u>	<u>15,152,270</u>
Loss from operations	(2,398,696)	(1,537,731)	(7,511,268)	(4,952,817)
Other income (expense), net				
Interest (expense) income, net	(154,999)	(19,705)	(2,380,972)	(61,699)
Change in derivative liability	-	-	(1,770)	-
Gain on sale of Infusionz and select assets	-	-	7,564,363	-
Gain (loss) on sale of property and equipment	-	5,500	-	5,500
Gain on SBA PPP loan extinguishment	-	-	-	300,995
Other income (expense), net	<u>(154,999)</u>	<u>(14,205)</u>	<u>5,181,621</u>	<u>244,796</u>
Net loss before income tax	(2,553,695)	(1,551,936)	(2,329,647)	(4,708,021)
Income tax benefit	496,880	1,351,686	449,828	1,116,653
<b>Net loss from continuing operations</b>	<u>(2,056,815)</u>	<u>(200,250)</u>	<u>(1,879,819)</u>	<u>(3,591,368)</u>
<b>Loss (income) from discontinued operations</b>	288,127	147,583	(50,291)	4,115,245
<b>Net loss attributable to non-controlling interest</b>	124,804	-	358,390	-
<b>Net (loss) income attributable to Upexi, Inc.</b>	<u>\$ (1,643,884)</u>	<u>\$ (52,667)</u>	<u>\$ (1,571,720)</u>	<u>\$ 523,877</u>
<b>Basic income (loss) per share:</b>				
Loss per share from continuing operations	<u>\$ (0.11)</u>	<u>\$ (0.01)</u>	<u>\$ (0.11)</u>	<u>\$ (0.22)</u>
Income (loss) per share from discontinued operations	<u>\$ 0.02</u>	<u>\$ 0.01</u>	<u>\$ (0.00)</u>	<u>\$ 0.26</u>
<b>Total (loss) income per share</b>	<u>\$ (0.11)</u>	<u>\$ (0.00)</u>	<u>\$ (0.11)</u>	<u>\$ 0.03</u>
<b>Diluted (loss) income per share:</b>				
Loss per share from continuing operations	<u>\$ (0.11)</u>	<u>\$ (0.01)</u>	<u>\$ (0.11)</u>	<u>\$ (0.20)</u>
Income (loss) per share from discontinued operations	<u>\$ 0.02</u>	<u>\$ 0.01</u>	<u>\$ (0.00)</u>	<u>\$ 0.23</u>
<b>Total (loss) income per share</b>	<u>\$ (0.11)</u>	<u>\$ (0.00)</u>	<u>\$ (0.11)</u>	<u>\$ 0.03</u>
Basic weighted average shares outstanding	<u>18,015,837</u>	<u>16,426,399</u>	<u>17,418,877</u>	<u>16,080,699</u>
Fully diluted weighted average shares outstanding	<u>18,015,837</u>	<u>17,821,810</u>	<u>17,418,877</u>	<u>17,586,030</u>

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

[Table of Contents](#)

**UPEXI, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)**

	<u>Preferred Stock Shares</u>	<u>Preferred Stock Par</u>	<u>Common Stock Shares</u>	<u>Common Stock Par</u>	<u>Additional Paid In Capital</u>	<u>Accumulated Deficit</u>	<u>Non-controlling Interest</u>	<u>Total Stockholders' Equity</u>
<b>2022</b>								
Balance, June 30, 2021	500,000	\$ 500	15,262,394	\$ 15,262	\$ 25,372,247	\$ (4,170,036)	\$ -	\$ 21,217,973
Issuance of common stock for acquisition of Infusionz	-	-	306,945	307	1,764,569	-	-	1,764,876
Issuance of common stock for acquisition of VitaMedica	-	-	100,000	100	481,900	-	-	482,000
Issuance of common stock for acquisition costs	-	-	7,000	7	33,733	-	-	33,740
Stock based compensation	-	-	-	-	593,098	-	-	593,098
Issuance of common stock for services	-	-	35,000	35	174,965	-	-	175,000
Net income for the three months ended September 30, 2021	-	-	-	-	-	511,711	-	511,711
Balance, September 30, 2021	500,000	\$ 500	15,711,339	\$ 15,711	\$ 28,420,512	\$ (3,658,325)	\$ -	\$ 24,778,398
Stock based compensation	-	-	-	-	677,455	-	-	677,455
Issuance of common stock for acquisition of Interactive Offers	-	-	666,667	667	3,999,333	-	-	4,000,000
Net income for the three months ended December 31, 2021	-	-	-	-	-	64,833	-	64,833
Balance, December 31, 2021	500,000	\$ 500	16,378,006	\$ 16,378	\$ 33,097,300	\$ (3,593,492)	\$ -	\$ 29,520,686
Stock based compensation	-	-	-	-	670,098	-	-	670,098
Repurchase common stock	-	-	(467,765)	(468)	(1,975,420)	-	-	(1,975,888)
Issuance of common stock for exercise of options	-	-	36,582	36	(36)	-	-	-
Issuance of common stock for stock compensation	-	-	91,500	92	183,823	-	-	183,915
Issuance of common stock for stock compensation for building remodel	-	-	70,000	70	70,280	-	-	70,350
Net loss for the three months ended March 31, 2022	-	-	-	-	-	(52,667)	-	(52,667)
Balance, March 31, 2022	<u>500,000</u>	<u>\$ 500</u>	<u>16,108,323</u>	<u>\$ 16,108</u>	<u>\$ 32,046,045</u>	<u>\$ (3,646,159)</u>	<u>\$ -</u>	<u>\$ 28,416,494</u>
<b>2023</b>								
Balance, June 30, 2022	500,000	\$ 500	16,713,345	\$ 16,713	\$ 34,985,597	\$ (6,270,886)	\$ 54,820	\$ 28,786,744
Amortization of common stock issuance for services	-	-	-	-	70,350	-	-	70,350
Stock based compensation	-	-	-	-	927,326	-	-	927,326
Net loss for the three months ended September 30, 2022	-	-	-	-	-	(2,597,515)	(148,005)	(2,745,520)
Balance, September 30, 2022	500,000	\$ 500	16,713,345	\$ 16,713	\$ 35,983,273	\$ (8,868,401)	\$ (93,185)	\$ 27,038,900
Amortization of common stock issuance for services	-	-	-	-	70,350	-	-	70,350
Stock based compensation	-	-	-	-	1,052,847	-	-	1,052,847
Issuance of common stock for acquisition of E-Core	-	-	1,247,403	1,247	5,998,753	-	-	6,000,000
Net loss for the three months ended December 31, 2022	-	-	-	-	-	2,669,679	(85,581)	2,584,098
Balance, December 31, 2022	500,000	\$ 500	17,960,748	\$ 17,960	\$ 43,105,223	\$ (6,198,722)	\$ (178,766)	\$ 36,746,195



Stock based compensation	-	-	-	-	1,146,299	-	-	1,146,299
Issuance of common stock for interest on note payable	-	-	134,000	134	606,870			607,004
Net loss for the three months ended March 31, 2023	-	-	-	-	-	(1,643,884)	(124,804)	(1,768,688)
Balance, March 31, 2023	<u>500,000</u>	<u>\$ 500</u>	<u>18,094,748</u>	<u>\$ 18,094</u>	<u>\$ 44,858,392</u>	<u>\$ (7,842,605)</u>	<u>\$ (303,570)</u>	<u>\$ 36,730,810</u>

*The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.*

**UPEXI, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

	<b>Nine Months Ended March 31,</b>	
	<b>2023</b>	<b>2022</b>
<b>Cash flows from operating activities</b>		
Net (loss) income from operations	(1,571,720)	523,877
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:		
Depreciation and amortization	4,203,756	902,426
Gain on sale of Infusionz and select assets	(7,564,363)	-
Gain on sale of assets	-	(5,500)
Inventory write-offs	34,328	140,000
Bad debt expense	-	1,000
Accrued interest on note receivable from Bloomios	(141,635)	-
Amortization of senior security original issue discount	(455,450)	-
Uncollected transition fees from Bloomios	(428,500)	-
Non-controlling interest	(358,390)	-
Change in deferred tax asset	(515,089)	156,204
Shares issued for services	-	358,915
Shares issued for finder fee	1,770	33,740
Stock based compensation	3,126,472	1,940,651
Changes in assets and liabilities, net of acquired amounts		
Accounts receivable	2,490,729	21,735
Inventory	2,293,866	(604,325)
Prepaid expenses and other assets	(28,090)	533,103
Operating lease payable	2,975	(17,062)
Accounts payable and accrued liabilities	2,488,065	731,726
Deferred revenue	(57,686)	85,030
Net cash provided by operating activities - Continuing Operations	3,521,038	4,801,520
Net cash used in operating activities - Discontinued Operations	-	(2,634,975)
Net cash provided by operating activities	3,521,038	2,166,545
<b>Cash flows from investing activities</b>		
Acquisition of Lucky Tail	(3,012,327)	-
Acquisition of VitaMedica, Inc., net of cash acquired	(500,000)	(2,574,589)
Acquisition of New England Technology, Inc.	(2,085,390)	-
Acquisition of Cygnet	(1,050,000)	-
Acquisition of Interactive Offers, net of cash acquired	-	(1,854,193)
Proceeds from the sale of Infusionz and selected assets	4,273,427	6,000
Acquisition of property and equipment	(278,683)	(5,649,100)
Net cash used in investing activities - Continuing Operations	(2,652,973)	(10,071,882)
Net cash (used in) provided by investing activities - Discontinued Operations	-	-
Net cash used in investing activities	(2,652,973)	(10,071,882)
<b>Cash flows from financing activities</b>		
Repayment of notes payable	(470,168)	(150,000)
Repayment of SBA note payable	(254,804)	-
Repayment of the senior convertible notes payable	(6,307,775)	-
Payment on line of credit, net	(6,826,338)	-
Proceeds on note payable on building	3,000,000	-
Stock repurchase program	-	(1,975,888)
Repayment on note payable on building	(97,744)	-
Proceeds from issuance of convertible debt	2,650,000	-
Proceeds on note payable, related party	1,470,000	-
Net cash used in financing activities - Continuing Operations	(6,836,829)	(2,125,888)
Net cash (used in) provided by financing activities - Discontinued Operations	-	-
Net cash used in financing activities	(6,836,829)	(2,125,888)
<b>Net decrease in cash - Continuing Operations</b>	<b>(5,968,764)</b>	<b>(7,396,250)</b>
<b>Net decrease in cash - Discontinued Operations</b>	<b>-</b>	<b>(2,634,975)</b>
<b>Cash, beginning of period</b>	<b>7,149,806</b>	<b>14,534,211</b>
<b>Cash, end of period</b>	<b>\$ 1,181,042</b>	<b>\$ 4,502,986</b>
<b>Supplemental cash flow disclosures</b>		
Interest paid	\$ 326,918	\$ -
Income tax paid	\$ -	\$ -
<b>Non-cash financing activities</b>		
Issuance of common stock for acquisition of Infusionz	\$ -	\$ 1,764,876
Issuance of common stock for acquisition of VitaMedica	\$ -	\$ 482,000
Issuance of debt for acquisition of VitaMedica	\$ -	\$ 1,000,000
Liabilities assumed from acquisition of LuckyTail	-	-
Issuance of common stock for acquisition of E-Core	\$ 6,000,000	\$ -
Liabilities assumed from acquisition of E-Core	\$ (7,712,168)	\$ -
Non-cash consideration received from Bloomios for the sale of Infusionz	\$ 18,000,000	\$ -
Operating assets designated as held for sale	\$ 6,446,210	\$ 6,786,289
Liabilities assumed from acquisition of VitaMedica	\$ -	\$ (309,574)
Issuance of stock for acquisition of Interactive	\$ -	\$ 4,000,000
Liabilities assumed from acquisition of Interactive	\$ -	\$ (1,099,993)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.



**UPEXI, INC.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**Note 1. Description of the Business**

Upexi is a multi-faceted brand owner with established brands in health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current customer database has been key to the year-over-year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.

The Company primarily conducts its business operations through the following subsidiaries:

- HAVZ, LLC, d/b/a/ Steam Wholesale, a California limited liability company
  - o SWCH, LLC, a Delaware limited liability company
  - o Cresco Management, LLC, a California limited liability company
- Trunano Labs, Inc., a Nevada corporation
- MW Products, Inc., a Nevada corporation
- Upexi Holding, LLC, a Delaware limited liability company
  - o Upexi Pet Products, LLC, a Delaware limited liability company
- VitaMedica, Inc, a Nevada corporation
- Upexi Enterprise, LLC, a Delaware limited liability company
  - o Upexi Property & Assets, LLC, a Delaware limited liability company
    - Upexi 17129 Florida, LLC, a Delaware limited liability company
  - o E-Core Technology, Inc.
- Interactive Offers, LLC (“Interactive”), a Delaware limited liability company
- Cygnet Online, LLC (“Cygnet”), a Delaware limited liability company, 55% owned

We operate throughout our locations in the USA with operations in Florida, California, Nevada, and Colorado through our various Brands and entities.

**Upexi** operates from our corporate location in Clearwater, Florida where direct to consumer and Amazon sales are driven by on-site and remote teams for all brands. The location also supports all the other locations with accounting, corporate oversight, day-to-day finances and all business growth and management operating from this location.

**VitaMedica** operates mainly from our California location with product development, fulfillment, and day-to-day operations from that location, primarily focused on our health and beauty products.

**Interactive Offers** operates from its Florida office with day-to-day operations supported by various off site remote positions, with much of the development team operating out of Portugal.

**Cygnet Online** operates from our South Florida location with a full on-site GMP warehouse and distribution center, day-to-day operations of our Amazon liquidation business team from this location with support of remote team members.

**LuckyTail** operates from our Clearwater, Florida location with sales and marketing driven by on-site and remote teams that operate Amazon and direct to consumer sales strategy and daily business operations for our pet products.

## Table of Contents

**E-Core Technology, Inc.** operates from offices in Massachusetts, New York, New Jersey, and Florida and uses third-party logistic providers to receive, store and distribute its products. E-Core Technology, Inc. focuses on name brand consumer electronics and offers several innovative distribution models based on retailer requirements and programs. In addition, E-Core operates Tytan Tiles a children's toy brand for popular magnetic tiles and building blocks.

**HAVZ, LLC, d/b/a/ Steam Wholesale** operates manufacturing and/or distribution centers in Henderson, Nevada supporting our health and wellness products, including those products manufactured with hemp ingredients and our overall distribution operations. We have continued to manage these operations with a corporate focus on larger opportunities that have warranted management focus and investments for the future.

## Business Acquisitions

On August 1, 2021, the Company completed an asset purchase agreement with Grove Acquisition Subsidiary, Inc., a Nevada corporation and wholly owned subsidiary of the Company and the members of VitaMedica Corporation, a California corporation to purchase all the assets and assume certain liabilities of VitaMedica. VitaMedica is a leading online seller of supplements for surgery, recovery, skin, beauty, health, and wellness.

On October 1, 2021, the Company completed an equity interest purchase agreement with Gyprock Holdings LLC, a Delaware limited liability company, MFA Holdings Corp., a Florida corporation and Sherwood Ventures, LLC, a Texas limited liability company to acquire all of the outstanding membership interest of Interactive Offers, LLC, a Delaware limited liability corporation.

On April 1, 2022, the Company completed a securities purchase agreement with a single investor to acquire 55% of the equity interest in Cygnet Online, LLC, a Delaware limited liability corporation. The agreement also enables the Company to purchase the remaining 45% over the following two years. On April 12, 2023, the Company entered a deal to acquire the remaining 45% interest for structured cash payments equaling \$1.95 million over the subsequent 12 months. The deal is expected to close the week of May 15, 2023.

On August 12, 2022, the Company completed an asset purchase agreement with GA Solutions, LLC, a Delaware limited liability company ("LuckyTail"), pursuant to which the Company acquired substantially all assets of LuckyTail. LuckyTail sells pet nail grinders and other pet products through various sales channels including some international sales channels.

On October 31, 2022, the Company and its wholly owned subsidiary Upexi Enterprise, LLC, completed a securities purchase agreement to purchase the outstanding stock of E-Core Technology, Inc. d/b/a New England Technology, Inc. ("E-Core"), a Florida corporation. E-Core distributes non-owned branded products to national retail distributors and has branded products in the toy industry that E-Core sells direct to consumers through online sales channels and to national retail distributors.

## Business Divested

On October 26, 2022, the Company executed a membership interest purchase agreement to sell 100% of the membership interests of Infusionz LLC, a Colorado limited liability company ("Infusionz"), included in the sale was all rights to Infusionz brands and the manufacturing of certain private label business. Infusionz was originally purchased by the Company in July of 2020. The divestiture of Infusionz and related private label manufacturing represents a strategic shift in our operations and will allow us to become a predominantly product distribution focused company for both our Company owned brands and non-owned brands. Accordingly, the results of the business were classified as discontinued operations in our condensed statements of operations and excluded from both continuing operations and segment results for all periods presented.

## Basis of Presentation and Principles of Consolidation

The Company's condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The condensed consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of March 31, 2023 and June 30, 2022.

## Table of Contents

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated in consolidation. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.

### Discontinued Operations

A discontinued operation is a component of an entity that has either been disposed of or that is classified as held for sale, which represents a separate major line of business or geographic area of operations and is part of a single coordinated plan to dispose of a separate line of business or geographical area of operations. In accordance with the rules regarding the presentation of discontinued operations, the assets, liabilities, and activity of Infusionz and certain manufacturing business have been reclassified as discontinued operations for all periods presented.

### Fair Value of Financial Instruments

ASC Topic 820, *Fair Value Measurement* ("ASC 820"), establishes a fair value hierarchy for instruments measured at fair value that distinguished between assumptions based on market data (observable inputs) and the Company's own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumption about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier fair value hierarchy that distinguishes between the following:

Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities.

Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature. For the three and nine months ended March 31, 2023, management believed it necessary to record a reserve against the debt and equity instruments obtained in the sale of Infusionz of \$8,500,000.

### Reclassification

Certain reclassifications have been made to the condensed consolidated financial statements as of and for the year ended June 30, 2022, and for the three and nine months ended March 31, 2022 to conform to the presentation as of and for the three and nine months ended March 31, 2023.

## Note 2. Acquisitions

### *VitaMedica Corporation*

Effective August 1, 2021, the Company purchased VitaMedica through Grove Acquisition Subsidiary, Inc., a Nevada corporation and wholly owned subsidiary of the Company from VitaMedica Corporation, a California corporation, David Rahm and Yvette La-Garde. VitaMedica Corporation is a leading online seller of supplements for surgery, recovery, skin, beauty, health and wellness.

The following table summarizes the consideration transferred to acquire VitaMedica and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$ 2,000,000
Cash, working capital adjustment	74,589
Common stock, 100,000 shares valued at \$4.82 per common share, the closing price on August 4, 2021.	482,000
Note payable	500,000
	<u>\$ 3,556,589</u>

Recognized amounts of identifiable assets acquired and liabilities assumed:

Accounts receivable	\$ 107,446
Inventory	619,837
Prepaid expenses	117,268
Property and equipment	13,220
Trade name	463,000
Customer list	1,329,000
Non-compete	143,000
Right of use asset	112,612
Accounts payable	(140,068)
Operating lease	(56,894)
Operating lease	(112,612)
Total identifiable net assets	<u>\$ 2,595,809</u>
Goodwill	<u>\$ 960,780</u>

No contingent consideration was recorded with this acquisition.

The goodwill is deductible for tax purposes and attributable to the Company's added ability to enter the online seller's market for surgery supplements, recovery, skin, beauty, health and wellness and provided improved gross margins through synergies recognized with the consolidation of manufacturing and distribution operations.

The Company's condensed consolidated financial statements for the three and nine months ended March 31, 2023 include the actual results for VitaMedica. For the three and nine months ended March 31, 2022, the Company's condensed consolidated financial statements include the actual results of VitaMedica for the period August 1, 2021 to March 31, 2022.

A finder's fee of \$103,740 was paid by the Company, \$70,000 in cash and 7,000 shares of common stock, valued at \$33,740, \$4.82 per common share, the closing market price on August 4, 2021 (close date of the transaction). These fees were expensed during the three and nine months ended March 31, 2022.

### *Interactive Offers, LLC*

Effective October 1, 2021, the Company acquired Interactive Offers, LLC, a Delaware limited liability company ("Interactive") from Gyprock Holdings LLC, a Delaware limited liability company, MFA Holdings Corp., a Florida corporation and Sherwood Ventures, LLC, a Texas limited liability company (each an "I/O Seller" and collectively the "I/O Sellers"). The I/O Sellers owned all the membership interests in Interactive. The Company's CEO and Chairman, Allan Marshall, was the controlling stockholder and the president of MFA Holdings Corp, which owned 20% of the outstanding membership interests in Interactive. Interactive provides programmatic advertising with its SaaS platform which allows for programmatic advertisement placement automatically on any partners' sites from a simple dashboard.

[Table of Contents](#)

The following table summarizes the consideration transferred to acquire Interactive and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$ 2,100,000
Common stock, 100,000 shares valued at \$4.88 per common share, the closing price on October 1, 2021.	2,733,630
	<u>\$ 4,833,630</u>

Recognized amounts of identifiable assets acquired and liabilities assumed:

Cash	\$ 245,247
Accounts receivable	23,791
Prepaid expenses	32,543
Property and equipment	3,212
Trade name	146,000
Customer list	763,000
Software	1,590,000
Non-compete	132,000
Accounts payable	(174,943)
Accrued liabilities	(313,800)
Accrued compensation	(24,193)
Deferred revenue	(478,385)
Total identifiable net assets	<u>\$ 1,944,472</u>
Goodwill	<u>\$ 2,889,158</u>

No contingent consideration was recorded with this acquisition.

The goodwill is deductible for tax purposes and attributable to the Company having a solid entry into the programmatic ad space and added a unique in-house advertising platform to leverage and scale its current and future brands. Access by sellers to Interactive's ad platform provides further product sales growth and advertising efficiencies. These are the factors of goodwill recognized in the acquisition.

The Company's condensed consolidated financial statements for the three and nine months ended March 31, 2023, include the actual results of Interactive.

#### **Cygnnet Online, LLC**

Effective April 1, 2022, the Company acquired 55% of Cygnnet Online, LLC, a Delaware limited liability company ("Cygnnet"). The Company purchased 55% of the equity in the business with a purchase price of \$5,515,756, as amended.

The following table summarizes the consideration transferred to acquire Interactive and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$ 1,500,000
Convertible note payable, convertible at \$6.00 per common share	1,050,000
Earnout payment	-
Common stock, 555,489 shares valued at \$5.34 per common share, the closing price on April 1, 2022.	2,965,756
	<u>\$ 5,515,756</u>

Recognized amounts of identifiable assets acquired and liabilities assumed:

Cash	\$ 471,237
Accounts receivable	860,882
Inventory	2,337,208
Prepaid expenses	6,900
Property and equipment	7,602
Right to use asset	410,365
Other asset	6,545
Online sales channels	1,800,000
Vendor relationships	6,000,000
Accrued liabilities	(701,606)
Notes payable	(7,298,353)
Operating lease	(422,479)
Total identifiable net assets	<u>\$ 3,478,301</u>
Goodwill	<u>\$ 2,037,455</u>

The Company's condensed consolidated financial statements for the three and nine months ended March 31, 2022, include the actual results of Cygnnet.

Commencing on October 10, 2022, and continuing for 180 days thereafter, the Company has the right, but not the obligation, to cause the Seller to sell 15% of the membership interests in Cygnnet for \$1,650,000 in immediately available funds. The Company did not exercise its right to purchase Seller's remaining membership interests in Cygnnet.

Commencing on the date that the Company completes its financial statements for the year ended December 31, 2023, and continuing for 120 days thereafter, the Company has the right, but not the obligation, to cause the Seller to sell the remaining 30% of the membership interests in Cygnnet for 30% of the amount equal to four times Cygnnet's Adjusted EBITDA (as defined in the Call Agreement) for calendar year 2023, payable by wire transfer of immediately available funds equal to at least 50% of said purchase price with the balance payable through the issuance to Seller of shares of restricted common stock of the Company.

The Seller has the right, but not the obligation, at any time commencing on the date that is 120 days after the date the Company completes Cygnnet's financial statements for the year ended December 31, 2023, and continuing for 90 days thereafter, to cause the Company to purchase all of the Seller's remaining membership interests in Cygnnet for a purchase price equal to the product of (i) four times Cygnnet's Adjusted EBITDA (as defined in the Put Agreement) for calendar year 2023, and (ii) the percentage of Cygnnet membership interests being sold, payable in shares of restricted common stock of the Company.

On April 12, 2023, the Company entered into an agreement to acquire the remaining 45% interest for structured cash payments equaling \$1.95 million over the subsequent 12



months. The deal is expected to close the week of May 15, 2023. If the deal does not close, the Seller's right to cause the Company to purchase all of the Seller's remaining membership interest would still be available to the Seller.

The acquisition of Cygnet provided the Company with the opportunity to expand its operations as an Amazon and eCommerce seller. The resulting combination increased Cygnet's product offerings through the Company's distributors and partnerships as it continues to focus on over-the-counter supplements and beauty products. Cygnet will be the anchor company for Upexi's Amazon strategy. These are the factors of goodwill recognized in the acquisition.

**LuckyTail**

Effective August 13, 2023, the Company acquired the business of LuckyTail from GA Solutions, LLC.

The following table summarizes the consideration transferred to acquire LuckyTail and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$	2,000,000
Cash payment, 90 days after close		500,000
Cash payment, 180 days after close		500,000
Contingent consideration		130,620
Cash payment, working capital adjustment		490,822
	\$	<u>3,621,442</u>

Recognized amounts of identifiable assets acquired and liabilities assumed:

Inventory	\$	490,822
Trade name		360,000
Customer list		2,304,000
Total identifiable net assets	\$	<u>3,154,822</u>
Goodwill	\$	<u>466,620</u>

The Company's condensed consolidated financial statements for the three and nine months ended March 31, 2023, include the actual results of LuckyTail from August 13, 2022, through March 31, 2023.

The Company agreed to purchase certain inventory from the Seller upon its valuation having been determined, at close the inventory and other current assets were agreed to be \$490,822, consisting of inventory and prepaid inventory. The asset purchase agreement also provides for a two-way post-closing adjustment based on a target adjusted revenue for the business acquired of \$1,492,329 for the period of August 1, 2022 through March 31, 2023. The Company adjusted its estimate of \$150,000 for this contingent consideration to \$130,320 with the offset to goodwill.

The acquisition of LuckyTail provided the Company with a foothold in the pet care industry and a strong presence on Amazon and its eCommerce store, offering nutritional and grooming products domestically and internationally. The acquisition provided both top line growth and improved EBITDA for the Company. These are the factors of goodwill recognized in the acquisition.

[Table of Contents](#)

***E-Core, Inc. and its subsidiaries***

Effective October 21, 2022, the Company acquired E-Core Technology, Inc. (“E-Core”) d/b/a New England Technology, Inc., a Florida corporation (“New England Technology”).

The following table summarizes the consideration transferred to acquire E-core and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$	100,000
Cash payment, 120 days		3,000,000
Note payable		5,750,000
Note payable 2		5,750,000
Convertible note payable, convertible at \$4.81 per common share		3,500,000
Common stock, 1,247,402 shares valued at \$4.81 per common share, the calculated closing price on October 21, 2023.		6,000,000
	\$	<u>24,100,000</u>

Recognized amounts of identifiable assets acquired and liabilities assumed:

Cash	\$	1,014,610
Accounts receivable		6,699,945
Inventory		7,750,011
Prepaid expenses		75,721
Trade name		1,250,000
Customer relationships		6,000,000
Accrued liabilities		(192,051)
Line of credit		(7,201,079)
Total identifiable net assets	\$	<u>15,397,157</u>
Goodwill	\$	<u>8,702,843</u>

In addition, on October 31, 2022, the Company issued options to purchase up to 360,000 shares of the Company’s common stock at an exercise price of \$5.30 per share.

The Company’s condensed consolidated financial statements for the three and nine months ended March 31, 2023, include the actual results of E-Core from October 21, 2022 through March 31, 2023.

The acquisition of E-Core provided the Company with an entrance into the children’s toy sector as well as national retail distribution for owned and non-owned branded products. The acquisition expands the Company’s ability to leverage direct-to-consumer distribution and further develop the broad distribution capabilities of E-Core. These are the factors of goodwill recognized in the acquisition.

***Revenue from acquisitions included in the financial statements.***

Net revenue included in the nine months ended:

	March 31,	
	2023	2022
VitaMedica	\$ 5,525,651	\$ 3,571,237
Interactive	1,054,935	1,543,651
Cygnat	20,806,317	
LuckyTail	3,579,727	-
E-Core	25,822,931	-
	<u>\$ 56,789,561</u>	<u>\$ 5,114,888</u>

[Table of Contents](#)

Net revenue included in the three months ended:

	March 31,	
	2023	2022
VitaMedica	\$ 1,964,387	\$ 1,164,971
Interactive	371,613	690,634
Cygnat	6,199,137	-
LuckyTail	1,360,493	-
E-Core	12,175,519	-
	<u>\$ 22,017,149</u>	<u>\$ 1,855,605</u>

**Consolidated pro-forma unaudited financial statements.**

The following unaudited pro forma combined financial information is based on the historical financial statements of the Company, VitaMedica, Interactive, Cygnat, LuckyTail and E-Core after giving effect to the Company's acquisitions as if the acquisitions occurred on July 1, 2021.

The following unaudited pro forma information does not purport to present what the Company's actual results would have been had the acquisitions occurred on July 1, 2021, nor is the financial information indicative of the results of future operations. The following table represents the unaudited consolidated pro forma results of operations for the three and nine months ended March 31, 2023 and the three and nine months ended March 31, 2022, as if the acquisitions occurred on July 1, 2021. The results of operations for VitaMedica, Interactive and Cygnat are included in the three and nine months ended March 31, 2023 and the results of operations for LuckyTail are included from August 13, 2022 to March 31, 2023.

Operating expenses have been increased for the amortization expense associated with the fair value adjustment of definite lived intangible assets of VitaMedica, Interactive, Cygnat, LuckyTail and E-Core by approximately \$41,363, \$50,329, \$175,000, \$54,000, and \$,145,833 per month, respectively.

<b>Pro Forma, Unaudited Nine months ended March 31, 2023</b>	<u>Upexi, Inc.</u>	<u>LuckyTail</u>	<u>E-Core</u>	<u>Proforma Adjustments</u>	<u>Proforma</u>
Net sales	\$ 62,863,128	\$ 892,270	\$ 12,905,836	\$ -	\$ 76,661,234
Cost of sales	\$ 36,904,527	\$ 137,088	\$ 11,177,032	\$ -	\$ 48,218,647
Operating expenses	\$ 33,469,868	\$ 383,476	\$ 1,050,602	\$ 561,721	\$ 35,465,667
Net income (loss) from continuing operations	\$ (1,879,818)	\$ 371,706	\$ 660,860	\$ (561,721)	\$ (1,408,973)
Basic income (loss) per common share	\$ (0.11)	\$ -	\$ 0.53	\$ -	\$ (0.08)
Weighted average shares outstanding	17,418,877	-	1,247,402	(693,001)	17,973,278

<b>Pro Forma, Unaudited Three months ended March 31, 2022</b>	<u>Upexi, Inc.</u>	<u>Cygnat</u>	<u>LuckyTail</u>	<u>E-Core</u>	<u>Proforma Adjustments</u>	<u>Proforma</u>
Net sales	\$ 4,426,898	7,527,927	\$ 1,389,012	\$ 11,191,296	\$ -	\$ 24,535,133
Cost of sales	\$ 1,098,137	6,372,432	\$ 274,175	\$ 9,947,860	\$ -	\$ 17,692,604
Operating expenses	\$ 4,866,492	695,574	\$ 766,952	\$ 638,501	\$ 1,124,499	\$ 8,092,018
Net income (loss) from continuing operations	\$ (200,250)	382,657	\$ 347,885	\$ 604,475	\$ (1,124,499)	\$ 10,268
Basic income (loss) per common share	\$ (0.01)	0.69	\$ -	\$ -	\$ -	\$ 0.00
Weighted average shares outstanding	16,426,399	555,489	-	1,247,402	-	18,229,290

<b>Pro Forma, Unaudited Nine months ended March 31, 2022</b>	<u>Upexi, Inc.</u>	<u>VitaMedica</u>	<u>Interactive</u>	<u>Cygnat</u>	<u>LuckyTail</u>	<u>E-core</u>	<u>Proforma Adjustments</u>	<u>Proforma</u>
Net sales	\$ 13,280,565	\$ 384,391	\$ 1,329,522	\$ 22,583,781	\$ 3,316,325	\$ 33,675,631	\$ -	\$ 74,570,215
Cost of sales	\$ 3,081,112	\$ 93,509	\$ -	\$ 19,117,296	\$ 836,530	\$ 29,793,652	\$ -	\$ 52,922,099
Operating expenses	\$ 15,152,270	\$ 255,286	\$ 1,816,464	\$ 2,086,722	\$ 1,738,091	\$ 2,718,407	\$ 3,128,348	\$ 26,895,588
Net income (loss) from continuing operations	\$ (3,591,368)	\$ 35,596	\$ (376,987)	\$ 1,147,971	\$ 741,703	\$ 1,178,491	\$ (3,128,348)	\$ (3,992,942)
Basic income (loss) per common share	\$ (0.22)	\$ 0.36	\$ (0.67)	\$ 2.07	\$ -	\$ 0.94	\$ -	\$ (0.22)
Weighted average shares outstanding	16,080,699	100,000	560,170	555,489	-	1,247,402	(462,336)	18,081,424

VitaMedica amortization expense of \$496,356 annually and \$41,363 monthly is based on the purchase price allocation report. For the nine months ended March 31, 2022, the proforma adjustment included \$41,363, one month of amortization expense.

[Table of Contents](#)

Interactive amortization expense at \$603,948 annually and \$50,329 monthly is based on the purchase price allocation report. For the nine months ended March 31, 2022, the proforma adjustment included \$150,987, three months of amortization expense.

The Company estimated the annual Cygnet amortization expense at \$2,100,000 annually and \$175,000 monthly, based on management's preliminary allocation of the purchase price. For the nine months ended March 31, 2022, the proforma adjustment included \$1,575,000, nine months of amortization expense and \$525,000, three months of amortization expense for the three months ended March 31, 2022.

The Company estimated the annual LuckyTail amortization expense at \$648,000 annually and \$54,000 monthly, based on management's preliminary allocation of the purchase price. For the nine months ended March 31, 2023, the proforma adjustment included \$27,000 of amortization expense for half a month. For the three months ended March 31, 2022, the proforma adjustment included \$162,000 of amortization and for the nine months ended March 31, 2022, the proforma adjustment included \$486,000 of amortization expense.

The Company estimated the annual E-Core amortization expense at \$1,750,000 annually and \$145,833 monthly, based on management's preliminary allocation of the purchase price. For the nine months ended March 31, 2023, the proforma adjustment included \$534,721 of amortization expense for the six months, three and two third a month. For the three months ended March 31, 2022, the proforma adjustment included \$437,499 of amortization and for the nine months ended March 31, 2022, the proforma adjustment included \$1,312,497 of amortization expense.

For the three and nine months ended March 31, 2023, the Company incurred acquisition related expenses of \$5,517 and \$358,300 respectively. For the three and nine months ended March 31, 2022, the Company incurred acquisition related expenses of \$22,507 and \$240,234 respectively.

These costs are primarily external legal, accounting and consulting services directly related to completed acquisitions, due diligence, and review of possible target acquisitions. These acquisition-related costs are included in the general and administrative expenses on the Company's condensed consolidated statements of operations.

**Note 3. Inventory**

Inventory consisted of the following:

	<b>March 31, 2023</b>	<b>June 30, 2022</b>
Finished goods	\$ 10,140,644	\$ 4,725,685

The Company periodically reviews its inventory and makes adjustments to net realizable value, as appropriate. .

During the three and nine months ended March 31, 2023, the Company wrote off inventory valued at \$0 and \$34,328, respectively. During the three and nine months ended March 31, 2022, the Company wrote off inventory valued at \$0 and \$140,000, respectively.

**Note 4. Property and Equipment**

Property and equipment consist of the following:

	<b>March 31, 2023</b>	<b>June 30, 2022</b>
Furniture and fixtures	\$ 172,662	\$ 51,273
Computer equipment	156,875	103,615
Internal use software	521,093	-
Manufacturing equipment	3,206,060	1,002,796
Leasehold improvements	90,245	2,144,341
Building	4,876,133	4,656,435
Vehicles	261,362	253,229
Property and equipment, gross	9,284,430	8,211,689
Less accumulated depreciation	(1,666,282)	(867,906)
	<u>\$ 7,618,148</u>	<u>\$ 7,343,783</u>

[Table of Contents](#)

Depreciation expense for the three months ended March 31, 2023 and 2022 was \$232,492 and \$143,537, respectively.

Depreciation expense for the nine months ended March 31, 2023 and 2022 was \$669,540 and \$390,116, respectively.

During the three and nine months ended March 31, 2022, the Company sold vehicles with a carrying value of \$500 for cash proceeds of \$6,000, which resulted in a gain on the disposal of \$5,500.

**Note 5. Intangible Assets**

**Intangible assets as of March 31, 2023:**

	<b>Estimated Life</b>	<b>Cost</b>	<b>Accumulated Amortization</b>	<b>Net Book Value</b>
Customer relationships	4 years	\$ 10,396,000	\$ 1,797,188	\$ 8,598,812
Trade name	5 years	2,219,000	339,584	1,879,416
Non-compete agreements	Term of agreement	275,000	253,395	21,605
Online sales channels	2 years	1,800,000	900,000	900,000
Vender relationships	5 years	6,000,000	1,200,000	4,800,000
Software	5 years	1,590,000	477,000	1,113,000
		<u>\$ 22,280,000</u>	<u>\$ 4,967,167</u>	<u>\$ 17,312,833</u>

For the three months ended March 31, 2023 and 2022, the Company amortized approximately \$1,691,243 and \$417,549, respectively.

For the nine months ended March 31, 2023 and 2022, the Company amortized approximately \$3,534,216 and \$1,085,481, respectively.

The following intangible assets were added during the nine months ended March 31, 2023 from the acquisition of LuckyTail:

Customer relationships	\$ 2,304,000
Trade name	360,000
Intangible Assets from Purchase	<u>\$ 2,664,000</u>

E-Core:

Customer relationships	\$ 6,000,000
Trade name	1,250,000
Intangible Assets from Purchase	<u>\$ 7,250,000</u>

**Intangible assets as of June 30, 2022:**

	<b>Cost</b>	<b>Accumulated Amortization</b>	<b>Net Book Value</b>
Customer relationships, amortized over four years	\$ 2,092,000	\$ 689,292	\$ 1,402,708
Trade name, amortized over five years	609,000	156,783	452,217
Non-compete agreements, amortized over the term of the agreement	275,000	115,042	159,958
Online sales channels, amortized over two years	1,800,000	225,000	1,575,000
Vender relationships, amortized over five years	6,000,000	300,000	5,700,000
Software, amortized over five years	1,590,000	238,500	1,351,500
	<u>\$ 12,366,000</u>	<u>\$ 1,724,617</u>	<u>\$ 10,641,383</u>

The following intangible assets were added during the year ended June 30, 2022, from the acquisition of VitaMedica, Interactive and Cygnet.

Customer relationships	\$ 2,092,000
Trade name	609,000
Non-compete agreements	275,000
Online sales channels	1,800,000
Vender relationships	6,000,000
Software	1,590,000
Intangible Assets from Purchase	<u>\$ 12,366,000</u>

Future amortization of intangible assets at March 31, 2023 are as follows:

June 30, 2023	\$ 1,381,700
June 30, 2024	5,240,905
June 30, 2025	4,560,800
June 30, 2026	4,560,800
June 30, 2027	1,568,628
Thereafter	-
	<u>\$ 17,312,833</u>

**Note 6. Prepaid Expense and Other Current Assets**

Prepaid and other receivables consist of the following:

	<b>March 31, 2023</b>	<b>June 30, 2022</b>
Insurance	\$ 218,046	\$ 32,045
Prepayment to vendors	399,627	175,378
Deposits on services	82,024	13,762
Prepaid monthly rent	6,900	6,900
Subscriptions and services being amortized over the service period	-	274,959
Prepaid sales tax	75,721	-
Other deposits	-	337,149
Stock issued for prepaid interest on convertible note payable	569,427	-
Other prepaid expenses	86,623	-
Cygnnet acquisition pre-payment	150,000	-
Amazon undeposited funds	221,362	-
Total	<u>\$ 1,809,730</u>	<u>\$ 840,193</u>

**Note 7. Operating Leases**

The Company has operating leases for corporate offices, warehouses and office equipment that have remaining lease terms of 1 year to 5 years.

The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized in the condensed consolidated balance sheet as of March 31, 2023:

2023	\$	94,255
2024		366,370
2025		153,458
2026		120,512
2027		28,684
Total undiscounted future minimum lease payments		763,279
Less: Imputed interest		(41,289)
Present value of operating lease obligation	\$	<u>721,990</u>

The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of March 31, 2023 are:

Weighted average remaining lease term	29 Months
Weighted average incremental borrowing rate	5.0%

For the three and nine months ended March 31, 2023, the components of lease expense, included in general and administrative expenses and interest expense in the condensed consolidated statement of operations, are as follows:

	<b>Three Months Ended March 31, 2023</b>	<b>Nine Months Ended March 31, 2023</b>
<b>Operating lease cost:</b>		
Operating lease cost	\$ 99,101	\$ 285,855
Amortization of ROU assets	67,088	233,409
Interest expense	4,595	25,030
Total lease cost	<u>\$ 170,784</u>	<u>\$ 544,294</u>

**Note 8. Accrued Liabilities and Acquisition Payable**

Accrued liabilities consist of the following:

	<b>March 31, 2023</b>	<b>June 30, 2022</b>
Accrued expenses for loyalty program	\$ -	\$ 6,418
Accrued interest	504,892	147,887
Accrued vendor liabilities	153,468	29,960
Accrued expenses on credit cards	476,802	108,735
Accrued sales tax	155,990	108,425
Derivative liability	-	81,909
Accrued expenses from sale of manufacturing operations	1,724,110	-
Other accrued liabilities	1,157,193	471,993
	<u>\$ 4,172,455</u>	<u>\$ 955,327</u>



[Table of Contents](#)

Acquisition Payable consist of the following:

	March 31, 2023	June 30, 2022
Payments related to the acquisition of LuckyTail	\$ 500,000	\$ -
	<u>\$ 500,000</u>	<u>\$ -</u>

The payable is estimated by management and due to the sellers of the acquisition and include the original purchase price installment payments not represented with a debt, equity or other instrument, estimates of excess or deficiencies in working capital and estimates of future earnout payments. This acquisition payment has been made as of May 15, 2023.

#### Note 9. Convertible Promissory Notes and Notes Payable

Convertible promissory notes and notes payable outstanding as of March 31, 2023 are summarized below:

	Maturity Date	March 31, 2023
Convertible Notes, 36-month term notes, 0% cash interest, collateralized with all the assets of the Company	October 31, 2025	\$ 3,500,000
Subordinated Promissory Notes, 24-month term notes, 4% cash interest, collateralized with all the assets of the Company	October 31, 2024	5,750,000
Subordinated Promissory Notes, 12-month term notes, 4% cash interest, collateralized with all the assets of the Company	October 31, 2023	5,750,000
Marshall Loan, 2-year term note, 8.5% cash interest, 3.5% PIK interest and subordinate to the Convertible Notes	June 28, 2024	1,401,734
Mortgage Loan, 10-year term note, 4.8% interest, collateralized by land and warehouse building	September 26, 2032	2,902,256
Promissory Note, 21- month term note, 18.11% interest payable with common stock and subordinate to the Convertible Notes	November 22, 2024	2,150,000
Promissory Note, 21-month term note, 10% cash interest and subordinate to the Convertible Notes	November 22, 2024	503,714
SBA note payable, 30-year term note, 6% interest rate and collateralized with all assets of the Company	October 6, 2031	3,961,444
Inventory consignment note, 60 monthly payments, with first payment due June 30, 2022, 3.5% interest rate and no security interest in the assets of the business	June 30, 2027	1,138,094
Line of Credit, \$10,000,000 inventory and accounts receivable line of credit, interest rate of prime minus ½% payable monthly, \$4,935,545 available at March 31, 2023		374,741
GF Note, 6 annual payments, with first payment due December 31, 2022, 3.5% interest rate and no security interest in the assets of the business	November 7, 2026	683,968
Total notes payable		<u>28,115,951</u>
Less current portion of notes payable		<u>9,164,189</u>
Notes payable, net of current portion		<u>\$ 18,951,762</u>

[Table of Contents](#)

Future payments on notes payable are as follows:

**For the year ended June 30:**

2023	\$ 1,383,520
2024	9,056,433
2025	10,537,645
2026	2,326,625
2027	994,333
Thereafter	3,971,947
	<u>\$ 28,270,503</u>
Convertible notes, original discount and related fees and costs	(154,552)
	<u>\$ 28,115,951</u>

On June 3, 2020, the Company entered into a loan for \$150,000 with the Small Business Administration. The promissory note has a fixed payment schedule commencing on June 3, 2021, consisting of principal and interest payments of \$731 monthly. The balance of the principal and interest will be payable thirty years from the date of the promissory note. The note bears interest at a rate of 3.75% per annum. The Company repaid this note in August of 2022 and the UCC has been terminated.

On August 1, 2021, the Company entered into a non-negotiable convertible promissory note related to the purchase of VitaMedica in the original principal amount of \$500,000 (“VitaMedica Note”), convertible at \$5.00 per share for a total of 100,000 shares of Company Common Stock. The Company repaid the note in full during August of 2022.

On April 15, 2022, the Company entered into a non-negotiable convertible promissory note in the original principal amount of \$,050,000, as adjusted, (“Cygnnet Note”) which can be converted into common stock of the Company at a price of \$6.00 per share and is payable in full, to the extent not previously converted, on April 15, 2023.

In June 2022, the Company entered into a securities purchase agreement with two accredited investors pursuant to which the Company could receive up to \$5,000,000 during the following twelve months of the agreement. The Company received \$6,678,506 for Convertible Notes in the original principal amount of \$7,500,000 (the “Convertible Notes”), representing the original purchase amount, less fees, costs and a \$500,000 holdback by the investors. In addition to the Convertible Notes, the investors received Common Stock Purchase Warrants (the “Warrants”) to acquire an aggregate of 56,250 shares of common stock. The Warrants are exercisable for five years at an exercise price of \$4.44 per share, provide for customary anti-dilution protection, and an investor put right to require the Company to redeem the Warrants for a total of \$250,000. There was a loss of \$1,770 for the change in the derivative liability for the period ended March 31, 2023. On October 31, 2022, the Company entered into a letter agreement with the accredited investors in which all amounts owed were paid in full and the related convertible notes and all security interests were cancelled. Additionally, the Company terminated the related Form S-3 registration statement.

In June 2022, the Company executed a promissory note with Allan Marshall, the Company’s Chief Executive Officer, in the original principal amount of \$1,500,000 (“Marshall Loan”). The promissory note has a 2-year term and bears cash interest at the rate of 8.5% per annum with an additional PIK of 3.5% per annum. The promissory note provides for monthly payments of principal, on an even line 36-month basis, plus cash interest, with a balloon payment of all outstanding principal, cash interest, and PIK interest at maturity. The Company received and deposited the principal amount on July 31, 2022.

On October 19, 2022, Upexi, Inc. (the “Company”) and its indirect wholly owned subsidiary, Upexi 17129 Florida, LLC entered into a loan agreement, promissory note and related agreements with Professional Bank, a Florida state-chartered bank, providing for a mortgage on the Company’s principal office in N. Clearwater, Florida. The Company received \$3,000,000 in connection with the transaction. The principal is to be repaid to Professional Bank over a term of ten years. The proceeds of the loan were utilized by the Company to pay down its loan facility with Acorn Capital, LLC in the amount of \$2,780,200.

On October 31, 2022, the Company and its wholly owned subsidiary, Upexi Enterprises, LLC entered into a securities purchase agreement with E-Core Technology, Inc. d/b/a New England Technology, Inc., a Florida corporation, and its three principals. The Company entered into a series of promissory notes with the principal parties: (a) promissory notes in the total original principal amount of \$5,750,000 payable upon maturity with a term of 12 months at an interest rate of 4%, \$600,000 of which shall be satisfied through the cancellation of an equal amount owed by one of the principals to the Company; (b) promissory notes in the total original principal amount of \$5,750,000 payable upon maturity with a term of 24 months at an interest rate of 4%; and (c) promissory notes in the original principal amounts of \$3,500,000 with a term of 36 months at an interest rate of 0.0%. The principals may convert the notes into shares of the Company's restricted common stock at a conversion price equal to \$4.81. If the principals do not exercise their conversion rights, the principal balance of the notes will be paid in 12 equal monthly payments commencing on the two year anniversary of the issuance of the notes, subject to adjustments based on the Company's EBITDA over the term of the notes.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$1,150,000 together with the issuance of 134,000 restricted shares ("the PIK shares") of the Company's common stock at a price of \$4.53 per share. The promissory note has a 21-month term and bears interest at 8.11% payable with the PIK shares. The promissory note provides for 12 monthly payments of principal beginning on December 22, 2023, and PIK interest of restricted shares on the Effective Date of the promissory note. The Company shall have the right at any time to convert all or any part of the outstanding and unpaid principal into fully paid and non-assessable shares of common stock, or any shares of capital stock or other securities, together with the PIK shares at a price per conversion share equal to \$5.00.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$60,000. The promissory note has a 21-month term and bears cash interest at the rate of 10% per annum. The promissory note provides for monthly payments of interest beginning on March 22, 2023 and 12 monthly payments of principal beginning on December 22, 2023.

#### **Note 10. Related Party Transactions**

During the year ended June 30, 2022, the Company entered into a promissory note with a member of management. The loan was for \$500,000 and has a two-year term with an interest rate of 8.5% per annum with an additional PIK of 3.5% per annum.

On February 22, 2023, the Company entered into a promissory note with a relative of Allan Marshall, CEO and Director of the Company. The loan was for \$1,150,000 and has a 21-month term with an interest rate of 18.11% per annum payable with PIK shares of restricted common stock.

#### **Note 11. Equity Transactions**

##### ***Convertible Preferred Stock***

The Company has 500,000 shares of Preferred Stock issued and outstanding to Allan Marshall, CEO. The preferred stock is convertible into the Company's common stock at a ratio of 1.8 shares of preferred stock for a single share of the Company's common stock at the holder's option, has preferential liquidation rights and the preferred stock shall vote together with the common stock as a single class on all matters to which shareholders of the Company are entitled to vote at the rate of ten votes per share of preferred stock.

##### ***Common Stock***

During the nine months ended March 31, 2022, the Company issued 306,945 shares of common stock for the acquisition of Infusionz, the shares were valued at \$1,764,876.

During the nine months ended March 31, 2022, the Company issued 100,000 shares of common stock for the acquisition of VitaMedica, the shares were valued at \$82,000.

[Table of Contents](#)

During the nine months ended March 31, 2022, the Company issued 7,000 shares of common stock as a finder's fee, the shares were valued at \$3,740.

During the nine months ended March 31, 2022, the Company issued 35,000 shares of common stock for consulting services to be provided over 6 months. The shares were valued at \$175,000.

During the nine months ended March 31, 2022, the Company issued 666,667 shares of common stock for the acquisition of Interactive Offers, LLC, the shares were valued at \$4,000,000.

During the nine months ended March 31, 2023, the Company issued 1,247,403 shares of common stock for the acquisition of E-Core Technologies Inc. a Florida corporation, valued at \$6,000,000.

During the nine months ended March 31, 2023, the Company issued 134,000 shares of common stock for prepayment of interest on a note payable.

**Note 12. Stock Based Compensation**

The Board of Directors of the Company may from time to time, in its discretion grant to directors, officers, consultants and employees of the Company, non-transferable options to purchase common shares. The options are exercisable for a period of up to 10 years from the date of the grant.

The following table reflects the continuity of stock options for the nine months ended March 31, 2023:

A summary of stock option activity is as follows:

	<b>Options Outstanding</b>	<b>Weighted Average Exercise Price</b>	<b>Average Remaining Contractual Life (Years)</b>	<b>Aggregated Intrinsic Value</b>
Outstanding at June 30, 2022	4,279,888	\$ 3.05	7.42	\$ 4,919,182
Canceled	(143,613)	1.21	-	-
Granted	897,000	2.52	10	-
Options outstanding at March 31, 2023	5,033,275	\$ 3.38	6.42	\$ 4,724,980
Options exercisable at March 31, 2023 (vested)	3,894,776	\$ 3.04	6.72	\$ 4,550,343

Stock-based compensation expense attributable to stock options was \$1,019,883 and \$670,098 for the three months ended March 31, 2023 and 2022, respectively. Stock-based compensation expense attributable to stock options was \$3,000,057 and \$1,940,651 for the nine months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 there was \$3,154,841 of unrecognized compensation expense related to unvested stock options outstanding, and the weighted average vesting period for those options was approximately 1.75 years.

The value of each grant is estimated at the grant date using the Black-Scholes option model with the following assumptions for options granted during the nine months ended March 31, 2023:

	<b>March 31, 2023</b>
Dividend rate	-
Risk free interest rate	2.07–4.06%
Expected term	5
Expected volatility	70-77%
Grant date stock price	\$3.87 - \$5.30

The basis for the above assumptions are as follows: the dividend rate is based upon the Company's history of dividends; the risk-free interest rate for periods within the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant; the expected term was calculated based on the Company's historical pattern of options granted and the period of time they are expected to be outstanding; and expected volatility was calculated based upon historical trends in the Company's stock prices.

Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on historical experience of forfeitures, the Company estimated forfeitures at 0% for each of the nine months ended March 31, 2023 and 2022.

#### **Note 13. Income Taxes**

The Company computed the year-to-date income tax provision by applying the estimated annual effective tax rate to the year-to-date pre-tax income and adjusted for discrete tax items in the period. The Company's income tax benefit was \$496,880 and \$449,828 for the three and nine months ended March 31, 2023, respectively. The Company's income tax benefit was \$1,351,686 and \$1,116,653 for the three and nine months ended March 31, 2022, respectively.

The income tax benefit for the three and nine months ended March 31, 2023, was primarily attributable to federal and state income taxes and nondeductible expenses for an effective tax rate of approximately 20.67%. For the three and nine months ended March 31, 2023, the difference between the U.S. statutory rate and the Company's effective tax rate are the book to tax differences and the net operating loss allocation at the state income tax level.

Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. The Company periodically evaluates the realizability of its net deferred tax assets based on all available evidence, both positive and negative. The Company also considered whether there was any currently available information about future years. The Company determined that it is more likely than not that the Company will have future taxable income to fully realize the Company's deferred tax asset.

As of March 31, 2023, there was approximately \$3,600,000 of losses available to reduce federal taxable income in future years and can be carried forward indefinitely.

#### **Note 14. Risks and Uncertainties**

There is substantial uncertainty and different interpretations among federal, state and local regulatory agencies, legislators, academics and businesses as to the scope of operation of Farm Bill-compliant hemp programs relative to the emerging regulation of cannabinoids. These different opinions include, but are not limited to, the regulation of cannabinoids by the U.S. Drug Enforcement Administration, or DEA, and/or the FDA and the extent to which manufacturers of products containing Farm Bill-compliant cultivators and processors may engage in interstate commerce. The uncertainties cannot be resolved without further federal, and perhaps even state-level, legislation, regulation or a definitive judicial interpretation of existing legislation and rules. If these uncertainties continue, they may have an adverse effect upon the introduction of our products in different markets.

In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company has transition to a combination of work from home and social distancing operations and there has been minimal impact to our internal operations from the transition. The Company is unable to determine if there will be a material future impact to its customers' operations and ultimately an impact to the Company's overall revenues.

#### **Note 15. Discontinued Operations – Sale of Infusionz to Bloomios**

On October 28, 2022, the Company determined that the best course of action related to Infusionz, LLC and certain manufacturing business was to accept an offer to sell those operations. The business will continue to operate during the transition period and management intends to continue to employ some of the workforce in the consolidation of other acquisitions and the overall operations of the business. The Company is reimbursed by Bloomios for purchases of raw materials and other expenses outlined in the agreement, which are offset against any customer invoices collected on behalf of Bloomios.

[Table of Contents](#)

The Company received from Bloomios, Inc.(OTCQB:BLMS), the purchaser (i) \$5,500,000 paid at closing; (ii) a convertible secured subordinated promissory note in the original principal amount of \$5,000,000; (iii) 85,000 shares of Series D convertible preferred stock, with a total stated value of \$8,500,000; (iv) a senior secured convertible debenture with a subscription amount of \$4,500,000, after original issue discount of \$779,117; and (v) a common stock purchase warrant to purchase up to 2,853,910 shares of Bloomios's common stock. The Company recorded the consideration received at the estimated value at the time of the transaction and as part of that estimate valued the additional warrants to purchase Bloomios shares of common stock at \$8,500,000 and a valuation allowance of \$8,500,000.

The assets transferred were recorded at their respective book values, the accrued and incurred expenses estimated by management were recorded and the consideration received was recorded at managements estimated fair value based on the balance sheet on October 26, 2022, the effective closing date.

Tangible assets, inventory / working capital*	\$ (1,344,000)
Tangible assets, warehouse and manufacturing equipment, net of accumulated depreciation*	(679,327)
Goodwill	(2,413,814)
Intangible assets, net of accumulated amortization	(946,996)
Accrued and incurred expenses related to the transaction and additional working capital*	(2,051,500)
Consideration received, including cash, debt and equity, net	15,000,000
Total gain recognized	<u>\$ 7,564,363</u>

\*During the continuing transition period, all of the inventory or working capital has not been transferred to the buyer.

During the transition period there are certain expenses and purchases incurred that are to be netted against funds collected on behalf of the buyer. On March 31, 2023, there was a receivable balance from the buyer of \$1,617,217, net.

Advance for payroll	\$ 50,000
Operating expense	608,517
Management fees	428,500
Excess working capital	388,565
Accrued interest	141,635
Total amounts due from Bloomios	<u>\$ 1,617,217</u>

These are recorded on the balance sheet as due from Bloomios. As of the date of this report, the Company continues to assist Bloomios under the transition agreement.

Investments - Bloomios:

Senior secured convertible debenture, net of unamortized original issue discount	\$ 4,955,450
Series D convertible preferred stock	8,500,000
Convertible Secured Subordinate Promissory Note	5,000,000
Reserve on Investments - Bloomios	(8,500,000)
Total Investments - Bloomios	<u>\$ 9,955,450</u>

*Senior Secured convertible debenture:*

The Company received a senior secured convertible debenture of \$4,500,000, net of the original issue discount. The Debentures have a maturity date of October 26, 2024, an interest rate of 10% and are convertible into shares of Bloomios common stock. The debenture contains customary representations, warranties and indemnification provisions. The Debentures are secured by a senior security interest in all assets of the Company and its subsidiaries.

In addition, the Company received a warrant to purchase shares of Bloomios common stock. The Company did not place any value on this warrant. Bloomios has agreed to use commercially reasonable efforts to complete a Qualified Offering within six months of October 26, 2022, to file a registration statement covering the resale of the warrant shares and the underlying shares convertible with the debenture.

*Series D convertible preferred stock*

85,000 shares of Series D preferred stock. The preferred shares have a stated value per share of \$100 and we are to receive dividends equal to 8.5% per year on a monthly basis, 30 days in arrears, for each month during which the Series D Preferred shares remain outstanding. The preferred stock shall not receive the declared dividends until the senior secured debentures are all repaid in full for all investors, including the debentures held by the Company.

*Convertible Secured Subordinate Promissory Note*

The note has an interest rate of eight and one-half percent (8.5%) per annum and requires Bloomios to make a prepayment to the note in the amount equal to 40% of the net proceeds received by Bloomios in connection with any offering of securities conducted in connection with an up listing. Interest is due on a monthly basis and the note is convertible, at the Company's option, into shares of Bloomios common stock at a conversion price of \$5.00 per share subject to adjustments. The full principal and interest is due on or before October 26, 2024.

The note is secured by a subordinated security interest in all assets of Infusionz pursuant to a certain pledge and security agreement, dated as of October 26, 2022, which security interest shall rank junior to all liens and security interests granted by Bloomios to the senior secured convertible note, which the Company is a holder of a portion of this security.

*Summary of discontinued operations:*

	<b>Three Months Ended March 31,</b>	
	<b>2023</b>	<b>2022</b>
<b>Discontinued Operations</b>		
Revenue	\$ -	\$ 5,844,690
Cost of sales	-	3,086,645
Sales, general and administrative expenses	-	1,764,754
Depreciation and amortization	(288,127)	200,353
Income (loss) from discontinued operations	288,127	792,918
Accounts receivable net of allowance for doubtful accounts	-	941,465
Fixed assets, net of accumulated depreciation	-	670,528
Total assets	-	8,330,573
Total liabilities	\$ -	\$ 167,008

	Nine Months Ended March 31,	
	2023	2022
<b>Discontinued Operations</b>		
Revenue	\$ 3,042,878	\$ 16,107,558
Cost of sales	\$ 1,803,643	\$ 8,127,404
Sales, general and administrative expenses	\$ 1,300,102	\$ 2,946,810
Depreciation and amortization	\$ 10,576	\$ 573,171
Income (loss) from discontinued operations, net of tax	\$ (50,291)	\$ 4,115,245
Accounts receivable net of allowance for doubtful accounts	-	\$ 941,465
Fixed assets, net of accumulated depreciation	-	\$ 670,528
Total assets	-	\$ 8,330,573
Total liabilities	\$ -	\$ 167,008

**Note 16. Subsequent Events**

On May 12, 2023, the Company agreed to sell 2,121,213 shares of common stock for a purchase price of approximately \$7,000,000. After deducting the underwriter's commissions, discounts, and offering expenses payable by the company, the Company expects to receive net proceeds of approximately \$6,060,000. In addition, the Company issued warrants to purchase approximately 169,000 shares of the Company's common stock at a purchase price of \$4.774 per common share.



## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

### **General Overview**

As used in this current report and unless otherwise indicated, the terms “the Company”, “we”, “us” and “our” mean Upexi, Inc.

For the nine months ended March 31, 2022 the condensed consolidated financial statements of Upexi, Inc. include the accounts of the Company and its wholly-owned subsidiaries; Trunano Labs, Inc., a Nevada corporation, Steam Distribution, LLC, a California limited liability company; One Hit Wonder, Inc., a California corporation; Havz, LLC, d/b/a Steam Wholesale, a California limited liability company, One Hit Wonder Holdings, LLC a California corporation; SWCH LLC, a Delaware limited liability company; Cresco Management LLC, a California limited liability company, and VitaMedica, Inc. a Nevada corporation as of August 1, 2021, and Interactive Offers, LLC a Delaware limited liability corporation as of October 1, 2021.

For the nine months ended March 31, 2023, the condensed consolidated financial statements of Upexi, Inc. include all of the subsidiary accounts included in the condensed consolidated financial statements for the nine months ended March 31, 2022 and include the subsidiaries in which the Company holds a controlling financial interest as of March 31, 2023, which includes Cygnet Online, LLC a Delaware limited liability corporation, as of April 1, 2022, Upexi Pet Products, LLC (“LuckyTail”), a Delaware limited liability corporation as of August 12, 2022 and E-Core Technology, Inc. (“E-Core”) as of October 21, 2022.

All intercompany accounts and transactions have been eliminated as a result of the consolidation.

### **Operating Segments**

The Company’s financial reporting is organized into only one segment, product sales. The Company’s internal reporting for product sales is organized into three channels of distribution: Upexi, Inc. branded products, customers’ branded products and white label products that are sold under customer brands. These product sales are aggregated and viewed by management as one reportable segment due to their similar economic characteristics, products, production, distribution processes and regulatory environment.

### **Results of Operations**

The following summary of the Company’s operations should be read in conjunction with its unaudited condensed consolidated financial statements for the three months ended March 31, 2023 and 2022, which are included herein.

**Three Months Ended March 31, 2023, Compared to Three Months Ended March 31, 2022**

	March 31,		Change
	2023	2022	
Revenue	\$ 24,219,445	\$ 4,426,898	\$ 19,792,547
Cost of revenue	\$ 14,614,754	\$ 1,098,137	\$ 13,516,617
Sales and marketing expenses	\$ 3,476,918	\$ 1,085,823	\$ 2,391,095
Distribution costs	\$ 2,578,180	\$ 605,368	\$ 1,972,812
General and administrative expenses	\$ 2,878,255	\$ 1,970,276	\$ 907,979
Other operating expenses	\$ 3,070,034	\$ 1,205,025	\$ 1,865,009
Other (income)	\$ (154,999)	\$ (14,205)	\$ (140,794)
Net loss attributable to Upexi, Inc.	\$ (1,643,884)	\$ (52,667)	\$ (1,591,217)

The three months ended March 31, 2023 include three acquisitions completed after March 31, 2022. These acquisitions were Cygnet Online, LLC, our Amazon aggregation business, LuckyTail our initial brand in the pet industry with products and sales channels both domestic and international, and our most recent, E-Core our product distribution business, which also includes Tytan Tiles, a children's toy brand. These acquisitions, coupled with the elimination of the discontinued operations from the sale of Infusionz and certain manufacturing operations, has significantly reduced the value of a direct comparison of the prior year to the current operations.

Revenues increased by \$19,792,547 or 447% to \$24,219,445 compared with revenue of \$4,426,898 in the same period last year. The revenue growth was primarily the result of the three acquisitions and was offset from the sale of Infusionz. Management believes that there is significant opportunity in the next 12 months for organic growth within the newly acquired business and will focus the acquisition targets on businesses that will enhance our current products or allow the business to accelerate growth.

Cost of revenue increased by \$13,516,617 or 1,230% to \$14,614,754 compared with cost of revenue of \$1,098,137 in the same period last year. The cost of revenue growth was primarily related to the acquisition of three companies and offset with the sale of Infusionz. Gross profit increased by over \$6,275,000 compared to the prior year. Management will seek to improve the gross profit and the overall gross margin in the next 12 months as we are able to leverage the significant increase in our purchasing requirements and continue to consolidate our operations.

Sales and marketing expenses increased by \$2,391,095 or 220% compared with the same period last year. The increase in sales and marketing expenses was primarily related to the acquisitions, however management has aligned the marketing expenditures with the expected quarter over quarter growth strategy to decrease the overall percentage of sales and marketing costs to sales. We anticipate our advertising expenses will continue to fluctuate in the following quarters as we fully implement our overall brand marketing strategy.

Distribution costs increased \$1,972,812 or 326% compared with the same period last year. The increase in distribution costs was primarily related to the three acquisitions, offset by the sale of Infusionz and the classification of these expenses as part of discontinued operations. In addition, there continue to be increases in transportation costs and third-party provider rates, which management has implemented a strategy to change promotions, increase prices and adjust packaging to decrease the overall percentage of distribution costs to sales.

General and administrative expenses decreased by \$907,979 or 46% compared with the same period last year. As the Company has changed with the acquisitions and the sale of Infusionz, management has managed the general and administrative costs and will continue to implement strategies to decrease the percentage of general and administrative costs when compared to total sales.

Other operating expenses increased by \$1,865,009 or 155% compared with the same period last year. These expenses are primarily non-cash and increase based on the intangible assets created with acquisitions and the continued amortization of stock compensation.

[Table of Contents](#)

During the three months ended March 31, 2023, the Company had other expense of \$154,999 compared to \$14,205 in the prior year. The increase in other expense is related to the increase in interest expenses incurred from acquisition debt and some additional short-term debt obtained in fiscal year 2023.

The Company had a net loss of \$1,643,884 compared to a net loss of \$52,667 in the prior year. The increase in net loss is primarily related to the above-mentioned changes.

Management believes that the operations during the three months ended March 31, 2023, are more indicative of the future, except with certain strategies, such as the increase in sales and marketing spend and the sale of Infusionz and certain manufacturing business. We will continue to improve the gross profit, while reducing the general and administrative expenses as compared to the sales as the Company continues to focus on sales growth while continuing to improve net income through the consolidation of operations.

**Nine Months Ended March 31, 2023, Compared to Nine Months Ended March 31, 2022**

	March 31,		Change
	2023	2022	
Revenue	\$ 62,863,128	\$ 13,280,565	\$ 49,582,563
Cost of revenue	\$ 36,904,527	\$ 3,081,112	\$ 33,823,415
Sales and marketing expenses	\$ 9,210,303	\$ 3,821,081	\$ 5,389,222
Distribution costs	\$ 8,641,559	\$ 1,538,830	\$ 7,102,729
General and administrative expenses	\$ 8,287,779	\$ 6,556,627	\$ 1,731,152
Other operating expenses	\$ 7,330,228	\$ 3,235,732	\$ 4,094,496
Other income	\$ 5,181,621	\$ 244,796	\$ 4,936,825
Net (loss) income attributable to Upexi, Inc.	\$ (1,571,720)	\$ 523,877	\$ (2,095,597)

The nine months ended March 31, 2023 include three acquisitions completed after March 31, 2022. These acquisitions were Cygnet Online, LLC, our Amazon aggregation business, LuckyTail our initial brand in the pet industry with products and sales channels that sells both domestically and internationally and our most recent, E-Core, our product distribution business, which also includes Tytan Tiles, a children's toy brand. These acquisitions, coupled with the elimination of the discontinued operations from the sale of Infusionz and certain manufacturing operations, has significantly reduced the value of a direct comparison of the prior year to the current operations.

Revenues increased by \$49,582,563 or 373% to \$62,863,128 compared with revenue of \$13,280,565 in the same period last year. The revenue growth was primarily the result of the three acquisitions and was offset from the sale of Infusionz. The nine months ended March 31, 2023 only included five and a half months of revenue from E-Core, as the acquisition was effective October 21, 2022 and did not include a complete nine months of revenue from LuckyTail. Management believes that there is significant opportunity in the next 12 months for organic growth within the newly acquired business and will focus the acquisition targets on businesses that will enhance our current products or allow the business to accelerate growth.

Cost of revenue increased by \$33,823,415 or 1,098% to \$36,904,527 compared with cost of revenue of \$3,081,112 in the same period last year. The cost of revenue growth was primarily related to the acquisition of three companies and offset with the sale of Infusionz. The gross profit increase increased by over \$15,750,000 compared to the prior period. Management will seek to improve the gross profit and the overall gross margin in the next 12 months as we are able to leverage the significant increase in our purchasing requirements and continue to consolidate our operations.

Sales and marketing expenses increased by \$5,389,222 or 141% compared with the same period last year. The increase in sales and marketing expenses was primarily related to the acquisitions and an increased marketing spend in the quarter ended December 31, 2022. We anticipate our advertising expenses will continue to fluctuate in the following quarters as we fully implement our overall brand marketing strategy.

[Table of Contents](#)

Distribution costs increased \$7,102,729 or 462% compared with the same period last year. The increase in distribution costs was primarily related to the three acquisitions, offset by the sale of Infusionz and the classification of these expenses as part of discontinued operations. Management will continue to look at efficiencies and opportunities to manage these costs and maintain these costs as a percentage of revenue.

General and administrative expenses increased by \$1,731,152 or 26% compared with the same period last year. The Company continued to have additional costs incurred in the nine months ended March 31, 2023 related to the sale of Infusionz and the transition. Management will continue to manage the general and administrative costs and implement strategies to decrease the percentage of general and administrative costs as compared to total sales.

Other operating expenses increased by \$4,094,496 or 127% compared with the same period last year. These expenses are primarily non-cash and increase based on the intangible assets created with acquisitions and the continued amortization of stock compensation.

During the nine months ended March 31, 2023, the Company had other income of \$5,181,621 compared to other income of \$244,796 in the prior year. The income was related to the gain recognized from the sale of Infusionz and select manufacturing business and the gain from extinguishment of the SBA PPP loan in the prior year. In the current year, the income was offset with interest expenses incurred from the refinancing and early termination of debt obtained in June of 2022.

The Company had a net loss of \$1,571,720 compared to net income of \$523,877 in the prior year. The decrease in net income is primarily related to the above-mentioned changes.

**Liquidity and Capital Resources**

**Working Capital**

	<b>As of March 31, 2023</b>	<b>As of June 30, 2022</b>
Current assets	\$ 20,095,485	\$ 20,764,601
Current liabilities	17,682,429	9,302,756
Working capital	<u>\$ 2,413,056</u>	<u>\$ 11,461,845</u>

**Cash Flows**

	<b>Nine Months Ended March 31,</b>	
	<b>2023</b>	<b>2022</b>
Cash flows provided by operating activities – continuing operations	\$ 3,521,038	\$ 4,801,520
Cash flows used in investing activities – continuing operations	(2,652,973)	(10,071,882)
Cash flows used in financing activities – continuing operations	(6,836,829)	(2,125,888)
Cash flows used by operating activities – discontinued operations	-	(2,634,975)
Cash flows provided by (used by) investing activities – discontinued operations	-	-
Cash flows provided by (used by) financing activities – discontinued operations	-	-
Net decrease in cash during the period	<u>\$ (5,968,764)</u>	<u>\$ (10,031,225)</u>

[Table of Contents](#)

On March 31, 2023, the Company had cash of \$1,181,042, a decrease of \$5,968,764 from June 30, 2022.

Net cash from operating activities benefited from non-cash expenses of \$7,366,326, which were offset by the non-cash gains of \$8,589,948, primarily consisting of the gain from the sale of Infusionz and select manufacturing business and the amortization of the original issue discount of the senior security debt. Cash flow from operations decreased from the \$2,293,866 increase of inventory and the \$2,490,729 increase in accounts receivable.

Net cash used in investing activities for the nine months ended March 31, 2023 was \$2,652,973 and was primarily related to the \$4,273,427, net proceeds from the sale of Infusionz and select manufacturing business. This was offset by the \$500,000 final payment to the sellers of VitaMedica, the \$3,012,327 paid for the purchase of LuckyTail, the \$2,085,390 payment for the acquisition of New England Technology, net of acquired cash and the \$1,050,000 payment for the acquisition of Cygnet. For the period ended March 31, 2022, the use of cash was for the VitaMedica acquisition, the Interactive Offers purchase and the acquisition of property and equipment. The most significant purchase was the building located in Clearwater, Florida for approximately \$4,000,000.

Net cash used by financing activities for the nine months ended March 31, 2023, was \$6,836,829 compared to the use of \$2,125,888 during the nine months ended March 31, 2022. The cash used by financing activities was the repayment of \$6,826,338 to the line of credit, the repayment and termination of the senior convertible note and the installment payments of several other notes. The Company obtained a note from a related party and a mortgage on the building purchased in the prior year and received proceeds from the issuance of convertible debt. The funds obtained were used for investing activities and the repayment of the senior convertible note. \$1,975,888 of cash used for the period ended March 31, 2022, was for the stock repurchase program.

On October 19, 2022, the Company and its indirect wholly owned subsidiary, Upexi 17129 Florida, LLC entered into a loan agreement with Professional Bank, A Florida state-chartered bank, providing for a mortgage on the Company's principal office in N. Clearwater, Florida. The company received \$3,000,000 in connection with the transaction. The principal is to be paid back to Professional Bank over a term of ten years. The proceeds of the loan were utilized by the Company to pay down its loan facility with Acorn Capital, LLC in the amount of \$2,780,200, net of fees and other expenses.

On October 31, 2022, Upexi, Inc. (the "Company"), paid \$4,275,071 in principle, \$613,466 in accrued interest, \$250,000 for settlement of a Put Option and \$7,900 in miscellaneous fees for a total of \$5,146,437 to the holders of the \$15 million senior secured convertible notes entered into on June 28, 2022. The payment terminates the agreement with the noteholders. The Company also terminated the registration statement covering the senior secured notes payable.

In June 2022, the Company executed a promissory note with Allan Marshall, the Company's Chief Executive Officer, in the original principal amount of \$1,500,000 ("Marshall Loan"). The promissory note has a 2-year term and bears cash interest at the rate of 8.5% per annum with an additional PIK of 3.5% per annum. The promissory note provides for monthly payments of principal, on an even line 36-month basis, plus cash interest, with a balloon payment of all outstanding principal, cash interest, and PIK interest at maturity. The Company received and deposited the principal amount on July 31, 2022.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$2,150,000 together with the issuance of 134,000 restricted shares ("the PIK shares") of the Company's common stock at a price of \$4.53 per share. The promissory note has a 21-month term and bears interest at 18.11% payable with the PIK shares. The promissory note provides for 12 monthly payments of principal beginning on December 22, 2023, and PIK interest of restricted shares on the Effective Date of the promissory note. The Company shall have the right at any time to convert all or any part of the outstanding and unpaid principal into fully paid and non-assessable shares of common stock, or any shares of capital stock or other securities, together with the PIK shares at a price per conversion share equal to \$5.00.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$560,000. The promissory note has a 21-month term and bears cash interest at the rate of 10% per annum. The promissory note provides for monthly payments of interest beginning on March 22, 2023 and 12 monthly payments of principal beginning on December 22, 2023.

We estimate that we will have sufficient working capital to fund our operations over the twelve months following the date of the issuance of these condensed consolidated financial statements and meet all our debt obligations.

### **Off-Balance Sheet Arrangements**

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Not applicable.

### **Item 4. Controls and Procedures**

#### **Evaluation of Disclosure Controls and Procedures**

Under the supervision and with the participation of our senior management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 31, 2023 (the “Evaluation Date”). Based on this evaluation, our principal executive officer and principal financial and accounting officer concluded as of the Evaluation Date that our disclosure controls and procedures were not effective such that the information relating to us required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. This conclusion is based on findings that constituted material weaknesses. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s interim financial statements will not be prevented or detected on a timely basis.

In performing the above-referenced assessment, our management identified the following material weaknesses:

- (i) inadequate segregation of duties consistent with control objectives.
- (ii) lack of multiple levels of supervision and review.

We believe the weaknesses and their related risks are not uncommon in a company of our size because of the limitations in the size and number of staff. Due to our size and nature, segregation of all conflicting duties has not always been possible and may not be economically feasible. However, we plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes by the end of our 2023 fiscal year as resources allow:

- (i) Appoint additional qualified personnel to address inadequate segregation of duties and implement modifications to our financial controls to address such inadequacies; and
- (ii) We will attempt to implement the remediation efforts set out herein by the end of the 2023 fiscal year.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Management believes that despite our material weaknesses set forth above, our financial statements for the quarter ended March 31, 2023, are fairly stated, in all material respects, in accordance with U.S. GAAP.

#### **Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal controls over financial reporting (as defined in Rules 12a-15(f) and 15d-15(f) under Exchange Act) that occurred during the quarter ended March 31, 2023, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, the Company may become involved in litigation relating to claims arising out of its operations in the normal course of business. The Company is not involved in any pending legal proceeding or litigation, and, to the best of its knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of its properties is subject, which would reasonably be likely to have a material adverse effect on the Company.

**Item 1A. Risk Factors**

As a “smaller reporting company”, the Company is not required to provide the information required by this Item.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

All of the securities issued by the Company were issued pursuant to the exemption for transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder and corresponding state securities laws. For more information regarding the foregoing transaction, see Note 16 to our Unaudited Condensed Consolidated Financial Statements included herein.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
<a href="#">3.1(a)</a>	<a href="#">Amended and Restated Articles of Incorporation as filed as Exhibit 3.1 on form S-1 filed on 4/15/2021 is incorporated by reference</a>
<a href="#">3.1(b)</a>	<a href="#">Certificate of Amendment to Articles of Incorporation as filed as Exhibit 3.1 on form 8-K and filed on 8/17/2022 is incorporated by reference</a>
<a href="#">3.2</a>	<a href="#">Amended By-laws as filed as Exhibit 3.2 on Form S-1 filed on 4/15/2021 is incorporated by reference</a>
<a href="#">10.1</a>	<a href="#">Securities Purchase Agreement with E-Core Technology, Inc. dated as of October 31, 2022 as filed on form 10-Q and filed on 2/15/2023 is incorporate by reference.</a>
<a href="#">10.2</a>	<a href="#">Membership Interest Purchase agreement with Bloomios, Inc. dated as of October 26, 2022 as filed on form 10-Q and filed on 2/15/2023 is incorporate by reference.</a>
<a href="#">31.1*</a>	<a href="#">Certification of Principal Executive Officer, pursuant to Rule 13a-14a and 15-d-14a of the Securities Exchange Act of 1934</a>
<a href="#">31.2*</a>	<a href="#">Certification of Principal Financial Officer, pursuant to Rule 13a-14a and 15-d-14a of the Securities Exchange Act of 1934</a>
<a href="#">32.1*</a>	<a href="#">Certification of Principal Executive Officer, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>
<a href="#">32.2*</a>	<a href="#">Certification of Principal Financial Officer, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a>
<b>101**</b>	<b>Interactive Data File</b>
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

\* *Filed herewith.*

\*\* *Furnished herewith.*



**SIGNATURES**

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**UPEXI, INC.**

Dated: May 19, 2023

*/s/ Allan Marshall*

\_\_\_\_\_  
**Allan Marshall**  
President, Chief Executive Officer, and Director  
(Principal Executive Officer)

Dated: May 19, 2023

*/s/ Andrew J. Norstrud*

\_\_\_\_\_  
**Andrew J. Norstrud**  
Chief Financial Officer  
(Principal Financial Officer and Principal Accounting  
Officer)

## CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Allan Marshall, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Upexi, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 19, 2023

/s/ Allan Marshall

Allan Marshall,  
President, Chief Executive Officer and Director  
(Principal Executive Officer)

## CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew J. Norstrud, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Upexi, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 19, 2023

*/s/ Andrew J. Norstrud*

\_\_\_\_\_  
Andrew J. Norstrud,  
Chief Financial Officer  
(Principal Financial Officer and Principal Accounting  
Officer)

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Allan Marshall, President and Chief Executive Officer of Upexi, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

- (1) the quarterly report on Form 10-Q of Upexi, Inc. for the period ended March 31, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Upexi, Inc.

Dated: May 19, 2023

*/s/ Allan Marshall*

\_\_\_\_\_  
Allan Marshall  
President, Chief Executive Officer and Director  
(Principal Executive Officer)

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Andrew J. Norstrud, Chief Financial Officer of Upexi, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

- (1) the quarterly report on Form 10-Q of Upexi, Inc. for the period ended March 31, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Upexi, Inc.

Dated: May 19, 2023

*/s/ Andrew J. Norstrud*

\_\_\_\_\_  
Andrew J. Norstrud,  
Chief Financial Officer  
(Principal Financial Officer and Principal Accounting  
Officer)